Cost-effectiveness of second- or third-line treatment with tisotumab vedotin for metastatic or recurrent cervical cancer
{{output}}
Objective: To evaluate the cost-effectiveness of tisotumab vedotin (TV) versus single-agent chemotherapy in patients with recurrent or metastatic cervical cancer (r/mCC) after failure of first-line treatment, from the perspective... ...
